Welcome to our dedicated page for Healthequity SEC filings (Ticker: HQY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how custodial cash turns into revenue—and how shifting healthcare policy may impact it—means wading through dense HealthEquity reports. Each 10-K details millions in HSA assets, while every 8-K discloses new bank partnerships and acquisition costs. If you have ever searched for “HealthEquity insider trading Form 4 transactions� or tried to map service-fee trends across quarters, you know the challenge.
Stock Titan solves it. Our AI reads every HealthEquity quarterly earnings report 10-Q filing and highlights interchange income, member growth, and segment margins in plain English. Form 4 alerts surface HealthEquity Form 4 insider transactions real-time, so you can monitor executive activity without refreshing EDGAR. Need deeper context? Click any headline for concise notes that make HealthEquity SEC filings explained simply—no more scrolling through footnotes.
Whether you are comparing custodial spread in the HealthEquity annual report 10-K simplified, analysing CEO pay via the HealthEquity proxy statement executive compensation, or following surprise announcements with HealthEquity 8-K material events explained, our platform keeps every disclosure in one place. Practical use cases include: spotting HSA asset inflows before earnings, tracking regulatory risk language shift, and reviewing HealthEquity executive stock transactions Form 4 before material events. From HealthEquity earnings report filing analysis to understanding HealthEquity SEC documents with AI, all forms update instantly—giving you a head start on the numbers that drive this consumer-directed benefits leader.
HealthEquity, Inc. (HQY) � Form 4 insider filing
Director Stuart B. Parker reported the grant of 2,003 restricted stock units (RSUs) on 06/26/2025. The units were awarded at $0 cost and will vest in full at the company’s next annual shareholder meeting. Settlement in common shares is scheduled for 02/01/2028, or earlier upon a change-of-control, termination of service, or death, as defined in the 2024 Equity Incentive Plan.
Following the grant, Parker’s direct beneficial ownership rises to 21,835 HQY shares. No open-market purchases, sales, or derivative security exercises were reported, and Table II shows no option activity.
This filing reflects routine director equity compensation. While the transaction modestly increases insider alignment, the 2,003-share grant is immaterial relative to HealthEquity’s total shares outstanding and is unlikely to influence the company’s valuation or liquidity.
FAQ
What is the current stock price of Healthequity (HQY)?
What is the market cap of Healthequity (HQY)?
